useful for the research of the diabetic and Alzheimer's disease.

Anti Pyrraline Monoclonal Antibody


print

Background

Reaction of protein amino groups with glucose leads, through the early products such as a Schiff base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE). Recent immunological studies using anti-AGE antibody (6D12) demonstrated the presence of AGE-modified proteins in several human tissues: (1) human lens (nondiabetic and noncataractous), (2) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (3) diabetic retina, (4)@peripheral nerves of diabetic neuropathy, (5) atherosclerotic lesions of arterial walls, (6)β2-microglobulin forming amyloid fibrils in patients with hemodialysis-related amyloidosis, (7) senile plaques of patients with Alzheimer’s disease, (8) the peritoneum of CAPD patients, (9) skin elastin in actinic elastosis, and (10) ceriod/lipofuscin deposits. These results suggest a potential role of AGE-modification in normal aging as well as age-enhanced disease processes. This antibody named as 6D12 has been used to demonstrate AGE-modified proteins in these human tissues, indicating potential usefulness of this antibody for histochemical identification and biochemical quantification of AGE-modified proteins.

Pyrraline is one of the major Maillard compounds resulting from the reaction of glucose and amino coumpounds at slightly acidic pH. Using anti-pyrraline antibody, pyrraline was detected in sclerosed glomeruli from diabetic and normal old kidneys as well as in renal arteries with arteriosclerosis. Furthermore, it was detected in neurofibrillary tangles and senile plaques in brain tissue from patients with Alzheimer’s disease.


 AGEs Antibody Flyer [PDF]
 AGEs Antibody Flyer@(print file) [PDF]
Package Size 20μg (80μL/vial)
Format
Buffer
Mouse monoclonal antibody 0.25 mg/mL
Block Ace as a stabilizer, containing 0.1% Proclin as a bacteriostat
Storage Store below –20°C.
Once thawed, store at 4°C. Repeated freeze-thaw cycles should be avoided.
Clone No. H12
Subclass IgG1
Purification method The splenic lymphocytes from BALB/c mouse, immunized with pyrraline-HSA were fused to myeloma P3U1 cells. The cell line (H12) with positive reaction was grown in ascitic fluid of BALB/c mouse, from which the antibody was purified by Protein G affinity chromatography.
Working dilution for immunohistochemistry: about 2μg/mL; for ELISA: 0.1-0.5μg/mL

<Reference>
References for Pyrraline
A. Miyata S, Monnier V, (1992): Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline, J Clin Invest. 89(4) : 1102-1112
B. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stren D, Sayre LM, Monnier VM, Perry G,(1994): Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91(12) : 5710-5714
C. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, Tabaton M.(1998): Early glycoxidation damage in brains from Down’s syndrome. Biochem Biophys Res Commun 243(3) : 849-851

*These references are Pyrraline’s background, not examples of how Anti Pyrraline monoclonal antibody is used .
*This product was developed in conjunction with Meiji Milk Product Co.,LTD Institute of Health Science

References for AGEs antibody
1. Horiuchi, S.et al.: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction; Evidence for the presence of a common structure. J. Biol. Chem. 266: 7329, 1991.
2. Araki, N. et al.: Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267: 10211, 1992.
3. Miyata, T. et al.: β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J. Clin. Invest. 92: 1243, 1993.
4. Yamada, K et al.: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin. Nephrol. 42: 354, 1994.
5. Kume, S. et al.: Immunohistochemical and ultrasturactural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am. J. Pathol. 147 : 654, 1995.
6. Makino, H. et al.: Ultrastructure of nonenzymatically grycated mesangial matrix in diabetic nephropathy. Kidney International 48: 517, 1995.
7. Mori, T. et al.: Localization of advanced grycation end products of Maillard reaction in bovine tissues and their endocytosis by macrophage scavenger receptors. Exp. Molec. Pathol. 63:135, 1995
8. Miyata, T. et al.: Identification of pentosidine as a native structure for advanced glycation end products inβ2-Microglobulin forming amyloid fibrils in patients with dialysis-related amyloidsis. Proc. Natl. Acad. Sci. USA. 93: 2353, 1996
9. Kimura, T. et al.: Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci. Lett. 208: 53,1996.
10 Ikeda, K. et al.: Nε-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075,1996.

Product List

Product Name Cat# Quantity Price

Anti Pyrraline, - (Mouse) Unlabeled DataSheet

KAL-KH010

20 UG ¥55,000
$734

Anti Pyrraline, - (Mouse) Biotin DataSheet

KAL-KH010-01

20 UG ¥70,000
$934

Anti Pyrraline, - (Mouse) Horseradish Peroxidase DataSheet

KAL-KH010-02

20 UG ¥70,000
$934

“Anti Pyrraline Monoclonal Antibody” also belongs to the following categories.